Company: PTHS
Filing Date: 2025-03-27
Form Type: 10-K
Source: 0001753926-25-000503
Chunk: 230

Company: Pelthos Therapeutics Inc.
Filing Date: 2025-03-27
Form: 10-K
Item: Item 1
Chunk 230
---
.30 or $22.68 per share. There was an intrinsic value of $0 and
$0 as of December 31, 2024 and 2023, respectively.

The
Company recognized stock-based compensation expense related to option vesting amortization of $1,455,561 and $1,733,233 for
the years ended December 31, 2024 and 2023, respectively, which is included in general and administrative expenses in the consolidated
statements of operations.

As
of December 31, 2024, the unamortized stock option expense was $1,295,319. As of December 31, 2024, the weighted average period
for the unamortized stock compensation to be recognized is 1.75 years.

Warrants

The
following is an analysis of the stock warrant grant activity:

 Schedule
of analysis of the stock warrant grant

    Weighted Average  
    Weighted Average 

    Number of Shares  
    Exercise Price  
    Remaining Life 

    Stock Warrants 

    Outstanding December 31, 2023 
     —  
    $—  
     — 

    Granted 
     55,000  
    $7.50  
     4.99 

    Expired 
     —  
    $—  
     — 

    Exercised 
     —  
    $—  
     — 

    Outstanding December 31, 2024 
     55,000  
    $7.50  
     4.13 

    Exercisable December 31, 2024 
     55,000  
    $7.50  
     4.38 

    F-24 

A
summary of the status of the Company’s nonvested warrants as of December 31, 2024, and changes during the year ended December
31, 2024, is presented below:

 Schedule
of  nonvested warrants

    Non-vested
    Warrants
     
    Warrants

    Weighted-
    Average
    Exercise
    Price

    Non-vested at December 31,
    2023

    —

    $
    —

    Granted

    55,000

    $
    7.50

    Vested